A B S T R A C T Thymus-derived lymphocyte (T-cell) function, as determined in vivo by cutaneous reactivity to several antigens and in vitro by responsiveness to mitogens and antigens, was assessed in 14 patients infected with a variety of fungal organisms. While all patients manifested a normal frequency of peripheral blood T cells, only seven patients reacted to at least one of the antigens used for cutaneous testing and demonstrated normal in vitro T proliferative responses. Three patients exhibited cutaneous anergy but normal in vitro T-cell reactivity while four patients demonstrated persistent anergy and marked in vitro T-cell hyporeactivity which was independent of activity of infection, concurrent medication, or any associated disorders. The marked diminution of in vitro T-cell reactivity noted for these later four patients was not due to a deletion of antigenor mitogen-reactive cells. Thus, patients' cells which had been initially cultured for 7 days without any mitogenic or antigenic stimulus and which were subsequently washed and recultured with phytohemagglutinin, concanavalin A, or histoplasmin demonstrated a marked increase in their responsiveness. Moreover, this reactivity noted for recultured cells could be suppressed by a nonphagocytic, nonadherent, nonimmunoglobulin-bearing, sheep red blood cell rosette-forming population of cells isolated from the fresh peripheral blood mononuclear cells of the same patient. While these "regulator" T cells were capable of suppressing T-proliferative responses to antigens and mitogens, they did not diminish pokeweed mitogen-induced immunoglobulin synthesis by normal bone marrow-derived lymphocytes. Patients in whom suppressor "T" cells were found were at risk for relapsing, disseminated fungal infection.
INTRODUCTION
Several lines of evidence suggest that cell-mediated immunity or thymus-derived lymphocyte (T-cell)' function plays a crucial role in host defense against infection with fungal organisms. Thus, individuals manifesting defects in T-cell-mediated immunity which occur either with malignancy or which result from various therapeutic regimins appear to be at risk for fungal infections (1) . Moreover, patients with localized or disseminated fungal infection do manifest deficiencies in T-cell reactivity although it is difficult to decide whether the defect precedes or is secondary to the infection (2, 3) . Finally, individuals manifesting congenital defects in T-cell function are at risk for at least localized fungal infection when compared to patients manifesting isolated defects in bone marrow-derived lymphocyte (B cell) or humoral immunity (4, 5) .
In delineating abnormalities of T-cell-mediated immunity which may be implicated in the susceptibility to fungal infection, it is no longer tenable to consider only intrinsic abnormalities which may occur in effector cell populations. Compelling evidence now exists demonstrating that immunologic reactivity at the effector stage is subjected to both suppressive and amplifying influences, with net reactivity then representing a balance between these two regulatory antagonists (reviewed in reference 6). Thus, T-cell hyporeactivity to a given fungal antigen, for example, may not necessarily indicate an absence of T cells capable of reacting to that antigen, but may rather indicate a preponderance of suppressive or a lack of amplifying influences. Within this framework, we have investigated the in vivo and in vitro T-cell reactivity of 14 patients with localized or disseminated infection with a variety of fungal organisms. Our results indicate that marked, persistent T-cell dysfunction is manifest in a portion of these patients. Most importantly, this dysfunction is not due to an absence of T cells capable of reacting to antigens, but rather is due to the presence of a population of T cells which suppresses other, potentially reactive T cells. Moreover, this abnormality appears to place these patients at a high risk for both disseminated and relapsing infection with the same organism.
METHODS
Patients. All patients included in the study were evaluated by and cared for by members of the Division of Infectious Disease at the Mayo Clinic. Urine, peripheral blood, sputum, gastric washes, and other specimens were cultured for bacteria and fungi by the Department of Clinical Microbiology. Cutaneous testing to candida, mumps, trichophytan, purified protein derivative (PPD) (5 tuberculin U), SK/SD, and histoplasmin was performed on all patients. Erythema and induration were measured at 4, 12, 24, and 48 h later with only induration greater than 5 mm present at 48 h in response to candida, mumps, trichophytan, PPD, or histoplasmin or greater than 10 mm in response to SK/SD (10 U of streptokinase, 2.5 U of streptodornase) scored as positive reactivity.
Cell cultures. Mononuclear cell populations containing less than 5% granulocytes were obtained from heparinized peripheral blood by sedimentation over Ficoll-Hypaque (7) . These cells were washed and resuspended in RPMI 1640 medium which had been supplemented with penicillin (100 U/ml), streptomycin (100 jsg/ml), L-glutamine (2 mmol/ml), and fetal calf serum (5%; all from Grand Island Biological Co., Grand Island, N. Y.) which had been heated at 560C for i h. To 1.5 X 10' cells placed in microtiter wells was added three concentrations (4. (6.7 Ci/mmol) was added for the last 4 h of culture and the cells collected in a similar fashion. The filters were then placed in 2 ml of Aquasol (New England Nuclear) and the radioactivity measured in a liquid scintillation spectrometer. The arithmetic mean of triplicate samples was determined and the results are expressed as counts per minute. Unless otherwise specified, results represent maximal mitogen or antigen reactivity.
Lymphocyte subpopulations. Quantitation of T cells was performed by utilizing the sheep red blood cell (S-RBC) rosette technique (8) . To 0.1 ml of peripheral blood mononuclear cells (10-15 X 108 cells/ml suspended in RPMI) was added 0.1 ml of washed S-RBC (5 X 108 S-RBC/ml). 50 ,ul of human AB serum which had been absorbed with S-RBC and heated at 56'C for i h was added and the mixture incubated at 37°C for 15 min. The cells were then centrifuged at 50 g for 5 min, incubated at 4°C for 2 h, and gently resuspended by hand mixing. The frequency of small, round cells binding three or more S-RBCs was enumerated by light microscopy.
To obtain populations of cells enriched for immunoglobulin (Ig)-bearing lymphocytes (B cells) or T cells, S-RBC rosettes were formed as described above. Mononuclear cells binding S-RBC to their surface were then separated from cells not forming rosettes by centrifugation over Ficoll-Hypaque. Cells remaining at the top of the FicollHypaque as well as cells sedimenting to the bottom of the Ficoll-Hypaque were removed separately, and the S-RBC in each fraction lysed with Tris-buffered ammonium chloride (9) . The frequency of B cells in each layer was then determined by utilizing fluorescein-labeled anti-Ig which contained specificities for human K-and X-chains (10 Indeed, the mitogen reactivity noted for these four patients was substantially less than that noted for patients comparably ill with other disorders (systemic lupus erythematosus [SLE] and sarcoidosis). That the in vitro T-cell hyporeactivity noted for patients in group III did not merely represent some alteration in culture conditions is demonstrated in Fig. 1 . Thus, despite the cell density used in culture, the duration of culture or the mitogen concentration used, peripheral blood mononuclear cells from these patients were consistently less reactive than those from normals. Although not shown, similar data was obtained when peripheral blood mononuclear cells from the two patients with histoplasmosis were cultured with various concentrations of histoplasmin antigen. Viability of the cultured cells, as measured by exclusion of trypan blue, as well as the number of cells recoverable at the end of culture, was similar for normal individuals and patients in group III (75-85% viability, 30-40% cell recovery). Finally, the relative frequency of peripheral blood monocytes, as depicted by cytoplasmic esterase, was similar Suppressor T Colls for patients in group III (23±8%) and normal (21± 6%). Although the infecting organism and mean patient age was similar in all three patient groups, two clinical characteristics distinguished group III from group I and group II patients (Table II) . Firstly, three of the four patients in group III demonstrated involvement of more than one organ system and all four patients manifested blood, urine, or bone marrow cultures which were repeatedly positive for the infecting fungal organism. In contrast, involvement of more than one organ system was noted in 40 and 30% of group I and group II patients, respectively. Moreover, only one patient in group I and none of the patients in group II demonstrated positive blood, urine, or bone marrow cultures. Secondly, three of the four patients in group III had two to three episodes each of documented relapsing infection. That is, after appropriate antifungal therapy, these patients lacked either clinical or microbiologic evidence of active infection. However, after intervals ranging from 5 to 12 mo, three patients manifested disseminated infection with the same fungal organism. Relapsing infection was not noted in any patients in group I or group II despite the fact that these patients had been followed for periods ranging from 2 to 3 yr.
It is to be emphasized that the T-cell frequency, cutaneous reactivities, and in vitro mitogen and antigen reactivities included for three of the four anergic patients in group III represent 5-12 determinations performed over a 12-to 18-mo period (data for the fourth patient represents a single determination performed during the absence of active infection). The T-cell hypo- reactivity noted for these patients then was independent of concurrent medication or activity of infection. In only one patient (group I) could an associated granulomatosus disease such as sarcoidosis be detected, and in no patient was there evidence of an underlying malignancy. Thus, despite a normal frequency of peripheral blood T cells, 4 of 14 patients with fungal infections manifested severe, persistent defects of in vivo as well as in vitro T-cell reactivity. Moreover, these patients appeared to be at risk for disseminated, relapsing infection. It is these patients that provide the basis for the following immunologic studies. Effect of culture on T-cell reactivity. Recently it has been possible to demonstrate that T-cell hyporeactivity noted in a portion of patients with collagen vascular disease can be reversed by placing the cells in culture without any mitogenic or antigenic stimulus for 24 h (12-15). Presumably, this is due to the elution from T cells of antibodies which are directed against T-cell surface receptors and thus interfere with the interaction between various stimuli and the cell surface. To determine if the in vitro T-cell hyporeactivity noted for patients in group III was similarly reversible, the following experiments were performed. Peripheral blood mononuclear cells from three of the patients available for study were placed in culture without the addition of any mitogenic stimulus. At various intervals the cultures were removed and the cells and supernatant culture medium (Fig. 2) . This is contrasted to reactivities noted for recultured cells from either normal individuals or from three patients from group I and one patient from group II. A decrease in the mean responsiveness to PHA and only a 1*-fold increase in the mean responsiveness to Con A was noted for these individuals. Most importantly, while the fresh peripheral blood mononuclear cells from patients in group III with histoplasmosis were unresponsive, in vitro, to histoplasmin, recultured cells from the same patients demonstrated normal DNA synthetic responses to this antigen. Although not shown, the DNA synthetic response of recultured cells from group III patients to candida antigen was also comparable to that noted for recultured lymphocytes from candida-sensitive, normal individuals. Recultured mononuclear cells from normal individuals not demonstrating cutaneous reactivity to candida or histoplasmin did not react in vitro to these antigens. Unfortunately, changes in specific antigen reactivity which might occur among the recultured mononuclear cells from group III patients with cryptococcal infections could not be determined due to lack of suitable antigen. This increase in mitogen and antigen reactivity could not be accounted for by any significant quantitative change in T cells as the relative frequency of cells capable of forming rosettes with S-RBC was similar for recultured cells (79±8%) and fresh cells (72±4%) obtained either from normal individuals or from patients in group III. Moreover, isolation of T-and B-lymphocyte-enriched populations from mononuclear cells which had been initially cultured for 7 days demonstrated that the increased reactivity noted for recultured cells represented reactivity among T cells and not simply acquisition of antigen or mitogen reactivity by B lymphocytes (Table III) . Finally, no significant differences in either the total number of cells recovered or the viability of recovered cells was noted when recultured cells otbained from patients in group III or from normal individuals were compared. These findings suggest that T cells capable of reacting to mitogenic or antigenic stimuli do exist among mononuclear cells from patients in group III and that this reactivity can become manifest simply by culturing the cells for 7 days.
Suppression of reactive cultured cells by fresh nonphagocytic, nonadherent, rosette-forming lymphocytes. The near normal T-cell reactivity noted for patients' cultured cells could be explained by the generation of reactive cells, perhaps through some differentiation or maturation process occurring during the 7-day culture.
Alternatively, fresh mononuclear cells taken from patients in group III might contain reactive cells which were suppressed in their responsiveness by factors which Ig released into the culture medium was a Methods) and is represented in Fig. 4 (17) (18) (19) . Similarly, effector cells active in reactions of delayed hypersensitivity are subjected to augmenting and suppressing influences imposed by other T cells, B cells, and macrophages (6, (20) (21) (22) (23) . Additionally, both T-and B-cell reactivity can be affected by an increasing list of soluble substances which may be produced exogenously by other nonlymphoid cells (24) (25) (26) (27) (28) . This variety of mechanisms by which immunologic reactivity may be impaired is reflected by the heterogeneity of immunologic defects detected in patients with fungal infection; some of which are depicted by the three groups of patients indicated here and many of which have been reported previously (2, 3, (29) (30) (31) (32) (33) (34) . Thus, if one excludes abnormalities resulting either from concurrent disease, such as malignancy, or administration of exogenous drugs such as chemotherapeutic agents, transitory defects in both in vitro and in vivo cell-mediated immunity, abnormalities in in vitro proliferative responses but not in the elaboration of lymphokines, as well as normal proliferative responses accompanied by defects in either release or effect of lymphokines, have all been reported to occur in patients infected with various fungal organisms. Moreover, it is evident from the studies presented here and by others that there is a subpopulation of patients with fungal infection who demonstrate severe, persistent defects of their in vivo as well as in vitro T-cell reactivity (2, 30, 34) . The crucial finding demonstrated by this study is that this defect may not result from a lack of potentially reactive T cells but rather may result from a suppression of this reactivity by other non-Ig-bearing, nonphagocytic, S-RBC rosette-forming, and thus presumably T cells. As regards this latter point, we feel relatively confident that it is indeed a thymusderived lymphocyte which is mediating suppression of T-proliferative responses in group III patients. Thus, populations isolated from patients' fresh peripheral blood mononuclear cells which contained 92% rosette-forming, 4% Ig-bearing, and 10% monocytes did suppress reactivity of cultured cells. Alternatively, populations containing 10% T, 50% B, and 42% monocytes did not. Moreover 1/1, and 0.5/1 ratios of group III patients' T (obtained by nylon column purification) and normal B cells were not suppressed in their Ig production when compared to cell mixtures containing normal rather than patient's T cells. This then indicates that the failure of group III patient's cells to suppress Ig production in the experiments outlined in Fig. 4 was not simply a manifestation of using too few suppressor T cells. That B cells of group III patients are not inherently resistant to suppressive T influences is suggested by data demonstrating that T cells from a patient with acquired hypogammaglobulinemia can suppress Ig production by group III patients' B cells tenfold. The persistence of apparently normal humoral immune reactivity in these patients may play an important role in their surviving the fungal infection. Thus, while the T-cell defect may hinder the ability of the patients to completely clear the organism, thus predisposing them to relapsing infections, intact humoral responses to the organisms may provide sufficient "immunity" for them to cope with active infection. Additionally, the persistance of normal B-cell reactivity may account for the relative lack of other phenomena in these patients such as recurrent viral infections and the occurrence of malignancy which have been associated with T-cell defects.
Several other obvious questions concerning the regulatory defect in these patients remain unanswered. For example, factors leading to the generation of suppressor T cells, specifically as they relate to possible interactions between exposure to certain antigens and genetic factors governing immune responsiveness, are conjectural. In this regard, while the noted suppression was "nonspecific" in that T-proliferative responses to a variety of stimuli were suppressed, this does not imply that the suppressive regulatory influences were not induced by specific fungal antigens. Thus, while suppressive T cells might be generated in response to a specific antigenic challenge, soluble factors mediating the suppression might act irrespective of the antigen specificity of the reacting cells. Moreover, it is not evident whether or not the defect precedes or results from the fungal infection. Finally, whether the heterogeneity in immunologic reactivity noted for the three patient groups delineated here, as well as that noted among patients described elsewhere, represents quantitative rather than qualitative differences in basic defects, as suggested previously, is not known (3) .
Thus, defective in vivo and in vitro T-cell reactivity noted in a subpopulation of patients with a fungal infection appears to be due to an abnormality in the regulation of reactive T cells rather than to a depletion of these cells. While these studies raise several important questions concerning the regulation of immunologic reactivity in general, they also serve to emphasize the importance of abnormalities of immunoregulation in clinical disorders. Indeed, we have now been able to demonstrate that T-cell hypofunction noted in a variety of disorders, including collagen vascular disease, combined immunodeficiency disorders, and generalized viral infections, is not due to deletion of reactive T cells but rather is due to a preponderance of cell-associated suppressive regulatory forces. Such studies are important not only in advancing our knowledge of the regulation of immune reactivity, but also for providing rationale for therapy aimed at correcting the defect.
